Massachusetts Financial Firm Reduces ACADIA Pharmaceuticals Stake

Asset manager sells over 38,000 shares of biotech company in Q4 2025

Apr. 16, 2026 at 9:06am

Got story updates? Submit your updates here. ›

An extreme close-up of intricately engineered metal components from a large industrial banking vault, dramatically lit to represent the complex financial infrastructure behind institutional investments.A cinematic view of the heavy machinery and secure storage that underpins major institutional investment decisions.San Diego Today

Massachusetts Financial Services Co. MA, a major institutional investor, decreased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 3.4% during the fourth quarter of 2025, selling 38,243 shares of the biopharmaceutical company's stock.

Why it matters

ACADIA Pharmaceuticals is a prominent biotech firm focused on central nervous system disorders, and changes in major institutional ownership can signal shifts in investor sentiment or confidence around the company's prospects.

The details

According to a 13F filing, Massachusetts Financial Services Co. MA now owns approximately 1,072,483 shares of ACADIA Pharmaceuticals, or around 0.63% of the company's outstanding stock. The firm had previously held 1,110,726 shares. Several other hedge funds also adjusted their ACADIA Pharmaceuticals positions during the quarter, with some increasing and others decreasing their stakes.

  • Massachusetts Financial Services Co. MA filed its 13F report for the fourth quarter of 2025 on April 16, 2026.

The players

Massachusetts Financial Services Co. MA

A major institutional investment management firm based in Boston.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on developing therapies for central nervous system disorders, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by a prominent institutional investor could signal some uncertainty around ACADIA Pharmaceuticals' near-term prospects, though the company remains a significant holding in Massachusetts Financial Services' portfolio. Investors will likely watch for any further changes in major institutional ownership of ACADIA stock in the coming quarters.